Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
Provided By GlobeNewswire
Last update: Mar 20, 2025
Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25
Read more at globenewswire.comNASDAQ:TERN (10/29/2025, 3:00:08 PM)
8.14
-0.45 (-5.24%)
Find more stocks in the Stock Screener
TERN Latest News and Analysis
